Oramed wins Japanese patent approval, nears insulin pill Phase II; Activaero sees positive results in childhood asthma trials;

> Oramed ($ORMP) recieved a Japanese patent for its technology that allows the oral administration of drugs rather than their injected counterparts, including the long-awaited oral insulin pill for which the company is approaching Phase II trials. Release

> Activaero GmbH achieved positive results in a Phase II trial of its childhood asthma treatment that combines liquid budesonide and the company's controlled inhalation system. Release

> Hospira ($HSP), Delcath Systems ($DCTH), Valeant Pharmaceuticals ($VRX) and Alkermes ($ALKS)--all companies with a hand in drug delivery--are under the microscope in a study evaluating the impact of the Affordable Care Act. Release

> Medimetrics and NIZO's drug-delivering, remote-controlled pill IntelliCap, may now also be used as a mapping system of the gastrointestinal tract, detecting links to diseases such as obesity and diabetes. More

> SteadyMed Therapeutics received a $3 million term loan credit facility from Square 1 Bank. SteadyMed's lead product is the PatchPump, which allows the delivery of liquid-based drugs though a programmable system. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.